Celularity (CELU) Non-Current Debt (2023 - 2025)
Celularity's (CELU) quarterly Non-Current Debt came in at $36.5 million in Q2 2025, little changed quarter-over-quarter from $36.5 million in Q1 2025.
Powered by 
Analysis
Celularity (CELU) Non-Current Debt (2023 - 2025) Analysis & Trends
Celularity (CELU) has reported Non-Current Debt for 3 consecutive years, with $36.5 million the latest figure, recorded in Q2 2025.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $36.5 million in Q2 2025; TTM through Jun 2025 was $36.5 million, a N/A change from a year earlier, with the FY2024 full-year figure at $35.9 million, changed N/A from the prior year.
- Non-Current Debt was $36.5 million for Q2 2025 at Celularity, roughly flat from $36.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $36.5 million in Q1 2025 and troughed at $4.7 million in Q1 2023.
- A 3-year average of $26.1 million and a median of $35.9 million in 2024 frame the typical range for Non-Current Debt.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | - |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 100.26 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 93.88 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | - |
| 10 | Celularity | 36.35 Mn | 30.17 Mn | -3.27 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 36.49 Mn |
| Mar 31, 2025 | 36.49 Mn |
| Dec 31, 2024 | 35.93 Mn |
| Jun 30, 2023 | 17.03 Mn |
| Mar 31, 2023 | 4.75 Mn |